Every pitch deck should answer one simple question: Why should an investor believe this can become a real company?
I reviewed a diagnostic startup with an interesting concept. It reminded me of a common challenge I see in early-stage fundraising.
A compelling idea and a large market are important, but they’re rarely enough. Investors also want evidence that the company has moved beyond the concept. What has been built? What has been tested? What has been validated? Every piece of evidence helps reduce uncertainty.
Early-stage investors understand there is risk. They’re not looking for certainty—they’re looking for progress. The more tangible proof a company can provide that it is executing on its vision, the easier it becomes for investors to believe the business can succeed.
A great pitch deck doesn’t just describe an opportunity. It demonstrates that the company is already taking meaningful steps toward realizing it.
The observations shared in the From the ChaosBio Deal Room series are generalized lessons drawn from reviewing early-stage life sciences companies. Company identities, specific technologies, and other confidential details have been omitted or modified to protect confidentiality. The views expressed are my own and are intended solely for educational and discussion purposes.